Analysts Anticipate Xencor Inc (XNCR) Will Announce Earnings of -$0.27 Per Share

Equities research analysts expect Xencor Inc (NASDAQ:XNCR) to report earnings of ($0.27) per share for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Xencor’s earnings, with estimates ranging from ($0.49) to ($0.06). Xencor posted earnings per share of ($0.21) during the same quarter last year, which would suggest a negative year-over-year growth rate of 28.6%. The business is expected to announce its next quarterly earnings results on Tuesday, February 27th.

According to Zacks, analysts expect that Xencor will report full-year earnings of ($1.10) per share for the current financial year, with EPS estimates ranging from ($1.29) to ($0.85). For the next year, analysts expect that the business will report earnings of ($1.67) per share, with EPS estimates ranging from ($2.12) to ($1.15). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Xencor.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.04). Xencor had a negative return on equity of 15.26% and a negative net margin of 148.29%.

Several brokerages recently commented on XNCR. Zacks Investment Research reissued a “sell” rating on shares of Xencor in a research note on Saturday, January 13th. ValuEngine downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research note on Monday, October 23rd. BidaskClub downgraded shares of Xencor from a “sell” rating to a “strong sell” rating in a research note on Friday, December 15th. Piper Jaffray Companies reissued a “buy” rating and issued a $35.00 price objective on shares of Xencor in a research note on Sunday, November 12th. Finally, Cantor Fitzgerald began coverage on shares of Xencor in a research note on Wednesday, November 29th. They issued an “overweight” rating and a $33.00 price objective for the company. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $30.80.

In other Xencor news, major shareholder John S. Stafford III purchased 24,653 shares of the firm’s stock in a transaction on Wednesday, October 25th. The stock was purchased at an average cost of $20.01 per share, for a total transaction of $493,306.53. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder John S. Stafford III purchased 150,000 shares of the firm’s stock in a transaction on Friday, October 27th. The stock was acquired at an average price of $19.81 per share, with a total value of $2,971,500.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 278,535 shares of company stock valued at $5,526,936. Corporate insiders own 4.03% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Great West Life Assurance Co. Can increased its position in shares of Xencor by 158.9% during the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 4,005 shares during the period. Principal Financial Group Inc. acquired a new stake in shares of Xencor during the third quarter worth $201,000. Legal & General Group Plc increased its position in shares of Xencor by 4.5% during the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 385 shares during the period. Citadel Advisors LLC acquired a new stake in shares of Xencor during the second quarter worth $224,000. Finally, Voya Investment Management LLC increased its position in shares of Xencor by 25.4% during the second quarter. Voya Investment Management LLC now owns 16,793 shares of the biopharmaceutical company’s stock worth $355,000 after buying an additional 3,405 shares during the period. Institutional investors own 77.50% of the company’s stock.

Shares of Xencor (NASDAQ XNCR) opened at $21.56 on Friday. The firm has a market cap of $1,012.48, a P/E ratio of -21.56 and a beta of 2.09. Xencor has a twelve month low of $18.55 and a twelve month high of $28.64.

ILLEGAL ACTIVITY NOTICE: “Analysts Anticipate Xencor Inc (XNCR) Will Announce Earnings of -$0.27 Per Share” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2018/01/21/analysts-anticipate-xencor-inc-xncr-will-announce-earnings-of-0-27-per-share.html.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Get a free copy of the Zacks research report on Xencor (XNCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply